TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Cybin ( (TSE:CYBN) ).
Cybin Inc. has announced a registered direct offering of common shares and pre-funded warrants, raising approximately $175 million. The proceeds will be used to repay existing debt and fund the company’s clinical programs, including CYB003, CYB004, and CYB005, as well as for general corporate purposes. This financing, supported by prominent biotech investors, is expected to enhance Cybin’s operational capabilities and strengthen its position in the neuropsychiatry industry.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc. is a Phase 3 clinical stage neuropsychiatry company focused on revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
See more data about CYBN stock on TipRanks’ Stock Analysis page.